Breaking News Instant updates and real-time market news.

VRSK

Verisk Analytics

$157.83 /

+3.47 (+2.25%)

16:36
05/05/20
05/05
16:36
05/05/20
16:36

Verisk Analytics reports Q1 EPS $1.17, consensus $1.13

Reports Q1 revenue $689.8M, consensus $684.95M.Scott Stephenson, chairman, president, and CEO, said, "During these challenging times, we are laser-focused on providing uninterrupted great service and support to our customers while also protecting the well-being of our more than 9,000 Verisk teammates around the world. We're navigating through this time of uncertainty from a position of strength and will continue to invest in our business and our people to capitalize on our competitive advantages over the long-term."

  • 06

    May

  • 20

    May

VRSK Verisk Analytics
$157.83 /

+3.47 (+2.25%)

04/01/20 Baird
Verisk Analytics a good defensive long term core holding, says Baird
03/30/20 RBC Capital
Verisk Analytics initiated with a Sector Perform at RBC Capital
01/22/20 Baird
Verisk Analytics price target raised to $184 from $165 at Baird
01/22/20 Credit Suisse
Verisk Analytics price target raised to $155 from $150 at Credit Suisse

TODAY'S FREE FLY STORIES

General news
20-Yr Bond Settlement to be released at 00:00  01:45
06/01/20
06/01
01:45
06/01/20
01:45
 
Upgrade
Pearson upgraded to Buy from Neutral at Goldman Sachs » 21:48
05/31/20
05/31
21:48
05/31/20
21:48
PSO

Pearson

$5.80 /

+0.08 (+1.40%)

Goldman Sachs analyst…

Goldman Sachs analyst Katherine Tait upgraded Pearson to Buy from Neutral with a price target of 678 GBp, up from 625.2 GBp. The company is at an "inflection point" for organic growth in 2021, and fully embracing the industry shift and expanding its services to meet the changing needs of higher education Institutions "could drive meaningfully higher long-term value," Tait tells investors in a research note. The analyst views Pearson as attractively valued and sees 16% further upside in the shares.

ShowHide Related Items >><<
PSO Pearson
$5.80 /

+0.08 (+1.40%)

PSO Pearson
$5.80 /

+0.08 (+1.40%)

05/27/20
Fly Intel: Top five analyst downgrades
05/27/20 Berenberg
Pearson downgraded to Sell from Hold at Berenberg
04/28/20 AlphaValue
Pearson upgraded to Add from Reduce at AlphaValue
04/28/20 Barclays
Pearson price target lowered to 465 GBp from 520 GBp at Barclays
PSO Pearson
$5.80 /

+0.08 (+1.40%)

PSO Pearson
$5.80 /

+0.08 (+1.40%)

Recommendations
eBay price target raised to $51 from $44 at Baird » 21:45
05/31/20
05/31
21:45
05/31/20
21:45
EBAY

eBay

$45.39 /

+1.31 (+2.97%)

Baird analyst Colin…

Baird analyst Colin Sebastian raised the firm's price target on eBay to $51 from $44 and keeps an Outperform rating on the shares. To reflect strong e-commerce data points and quarter-to-date outperformance in volumes according to his firm's tracker, Sebastian increased eBay's Q2 gross merchandise volume growth estimate to 12%, which translates to above consensus $2.52B in revenues and 82c in earnings per share. The updated tracker data show modest deceleration in weekly volume, but the company's growth remains strong, Sebastian tells investors in a research note.

ShowHide Related Items >><<
EBAY eBay
$45.39 /

+1.31 (+2.97%)

EBAY eBay
$45.39 /

+1.31 (+2.97%)

05/26/20 Baird
eBay Q2 trends still appear strong, says Baird
05/12/20 Baird
eBay monthly volume trends remain elevated, says Baird
04/30/20 RBC Capital
eBay price target raised to $37 from $29 at RBC Capital
04/30/20 Baird
eBay should be bought opportunistically on pullbacks, says at Baird
EBAY eBay
$45.39 /

+1.31 (+2.97%)

EBAY eBay
$45.39 /

+1.31 (+2.97%)

EBAY eBay
$45.39 /

+1.31 (+2.97%)

EBAY eBay
$45.39 /

+1.31 (+2.97%)

Downgrade
Vail Resorts downgraded to Hold from Buy at Deutsche Bank » 21:41
05/31/20
05/31
21:41
05/31/20
21:41
MTN

Vail Resorts

$198.52 /

-1.22 (-0.61%)

Deutsche Bank analyst…

Deutsche Bank analyst Chris Woronka downgraded Vail Resorts to Hold from Buy.

ShowHide Related Items >><<
MTN Vail Resorts
$198.52 /

-1.22 (-0.61%)

MTN Vail Resorts
$198.52 /

-1.22 (-0.61%)

05/21/20 Credit Suisse
Vail Resorts initiated with an Outperform at Credit Suisse
04/28/20 Deutsche Bank
Vail Resorts price target raised to $197 from $183 at Deutsche Bank
04/02/20 Deutsche Bank
Vail Resorts price target lowered to $183 from $238 at Deutsche Bank
03/23/20 KeyBanc
Vail Resorts price target lowered to $200 from $225 at KeyBanc
MTN Vail Resorts
$198.52 /

-1.22 (-0.61%)

MTN Vail Resorts
$198.52 /

-1.22 (-0.61%)

MTN Vail Resorts
$198.52 /

-1.22 (-0.61%)

MTN Vail Resorts
$198.52 /

-1.22 (-0.61%)

Upgrade
China Tower upgraded to Hold from Sell at Deutsche Bank » 21:41
05/31/20
05/31
21:41
05/31/20
21:41
CHWRF

China Tower

$0.00 /

+ (+0.00%)

Deutsche Bank analyst…

Deutsche Bank analyst Peter Milliken upgraded China Tower to Hold from Sell.

ShowHide Related Items >><<
CHWRF China Tower
$0.00 /

+ (+0.00%)

04/02/20 Deutsche Bank
China Tower downgraded to Sell from Hold at Deutsche Bank
12/08/19 Deutsche Bank
China Tower upgraded to Hold from Sell at Deutsche Bank
11/29/19 Goldman Sachs
China Tower upgraded to Buy from Neutral at Goldman Sachs
Recommendations
Stifel boosts Circor target to $32 from $17, adds to Select List » 20:25
05/31/20
05/31
20:25
05/31/20
20:25
CIR

Circor

$16.18 /

+0.19 (+1.19%)

Stifel analyst Nathan…

Stifel analyst Nathan Jones raised the firm's price target on Circor to $32 from $17 and reiterates a Buy rating on the shares. The analyst also added the shares to Stifel's Select List as a top idea for investors. With the "portfolio cleaned" up and with discrete cash expenses for restructuring and the distributed valve exit being incurred over the next two quarters, investors "can comfortably look forward to clean results and much improved cash flow in 2021," Jones tells investors in a research note. The shares are likely to "re-rate significantly higher" and offer strong potential returns for investors as these attributes become more visible over the next couple of quarters, adds the analyst.

ShowHide Related Items >><<
CIR Circor
$16.18 /

+0.19 (+1.19%)

CIR Circor
$16.18 /

+0.19 (+1.19%)

12/30/19 Stifel
Stifel sees Crane's acquisition of Circor business accretive in 2020
09/17/19
Fly Intel: Top five analyst upgrades
09/17/19
Circor upgraded to Overweight at KeyBanc
09/17/19 KeyBanc
Circor upgraded to Overweight from Sector Weight at KeyBanc
CIR Circor
$16.18 /

+0.19 (+1.19%)

CIR Circor
$16.18 /

+0.19 (+1.19%)

Hot Stocks
Fly Intel: Top five weekend stock stories » 20:22
05/31/20
05/31
20:22
05/31/20
20:22
AMZN

Amazon.com

$2,442.37 /

+42.04 (+1.75%)

, AAPL

Apple

$317.94 /

-0.38 (-0.12%)

, TGT

Target

$122.50 /

+4.055 (+3.42%)

, ALXN

Alexion

$120.03 /

+5.595 (+4.89%)

, AMGN

Amgen

$230.13 /

+6.11 (+2.73%)

, TWTR

Twitter

$30.97 /

-0.63 (-1.99%)

, MSFT

Microsoft

$183.30 /

+2.06 (+1.14%)

, GOOG

Alphabet

$1,430.80 /

+14.43 (+1.02%)

, GOOGL

Alphabet Class A

$1,435.82 /

+17.61 (+1.24%)

, FB

Facebook

$223.10 /

-2.04 (-0.91%)

, COTY

Coty

$3.63 /

-0.56 (-13.38%)

, SAVE

Spirit Airlines

$12.96 /

+0.035 (+0.27%)

, LUV

Southwest

$32.11 /

-0.44 (-1.35%)

, DAL

Delta Air Lines

$25.19 /

-0.47 (-1.83%)

, STAY

Extended Stay America

$11.50 /

+0.17 (+1.50%)

, LIND

Lindblad Expeditions

$7.87 /

+0.2 (+2.61%)

, MPC

Marathon Petroleum

$35.13 /

-0.08 (-0.23%)

, LVS

Las Vegas Sands

$47.96 /

-0.62 (-1.28%)

, CTRE

CareTrust REIT

$18.62 /

-0.73 (-3.77%)

, VLO

Valero

$66.62 /

-0.59 (-0.88%)

, PSX

Phillips 66

$78.30 /

-0.35 (-0.45%)

, CQP

Cheniere Energy Partners

$33.91 /

+0.87 (+2.63%)

, BAESY

BAE Systems

$0.00 /

+ (+0.00%)

Catch up on the…

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Amazon (AMZN) scaled back deliveries and adjusted routes in cities including Chicago and Los Angeles, Apple (APPL) kept some outlets shut, while Target (TGT) extended store closures nationwide after the death of George Floyd sparked demonstrations across the country, Bloomberg's Spencer Soper and James Ludden reported. "We are monitoring the situation closely and in a handful of cities we adjusted routes or scaled back typical operations to ensure the safety of our teams," an Amazon spokeswoman told Bloomberg News. 2. According to a company's filing, "On May 28, 2020, Alexion Pharmaceuticals [ALXN] and Amgen [AMGN] entered into a Confidential Settlement and License Agreement to settle three inter partes review proceedings at the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office initiated by Amgen that the Company previously disclosed. Pursuant to the Settlement Agreement, the company and Amgen have agreed to file a motion with the PTAB to terminate each of the pending IPRs. In addition, effective March 1, 2025 (or an earlier date in certain circumstances), the company grants to Amgen (and its affiliates and certain partners) a non-exclusive, royalty-free, license under U.S. patents and patent applications related to eculizumab and various aspects of the eculizumab product that the company currently markets and sells under the tradename SOLIRIS. This license will allow Amgen (and its affiliates and certain partners), effective March 1, 2025, the right to make, have made, use, import, have imported, sell, have sold, offer for sale, have offered for sale, distribute, and have distributed in or for the U.S., an eculizumab product." 3. President Trump declared war on Twitter (TWTR), and Wall Street trembled, with the stock shedding 9% of its value from Wednesday to Friday as investors digested the financial implications of the company having the world's most powerful person-and its most loyal user-as a mortal enemy, Eric Savitz wrote in this week's edition of Barron's. While tech stocks have outperformed during the pandemic, the Twitter-White House spat brings back a bad memory from 2019 and could mean a return of the "tech lash," another challenge for stocks this summer, the author added. Twitter's 9% decline equated to $2.4B in lost market value, the publication notes, pointing out that a similar move applied to the tech giants, would be far more substantial. Microsoft (MSFT), Apple, Amazon, Alphabet (GOOGL), and Facebook (FB) have a combined market value of $5.6T. A 9% haircut comes to $500B, Savitz contended. 4. Coty (COTY) is set to appoint its fourth new chief executive in less than four years, as the cosmetics and fragrance maker strives to revive slumping sales and reduce its burdensome debt load, The Wall Street Journal's Ben Dummett and Sharon Terlep reported. Peter Harf, Coty's current chairman, will also assume the CEO role as soon as Monday, the authors noted, citing people familiar with the matter. 5. Spirit Airlines (SAVE), Southwest Airlines (LUV), Delta Air Lines (DAL), Extended Stay America (STAY), Lindblad Expeditions (LIND), Marathon Petroleum (MPC), Las Vegas Sands (LVS), CareTrust (CTRE), Valero Energy (VLO) and Phillips 66 (PSX), Cheniere Energy Partners (CQP), BAE Systems (BAESY) saw positive mentions in this week's edition of Barron's.

ShowHide Related Items >><<
VLO Valero
$66.62 /

-0.59 (-0.88%)

TWTR Twitter
$30.97 /

-0.63 (-1.99%)

TGT Target
$122.50 /

+4.055 (+3.42%)

STAY Extended Stay America
$11.50 /

+0.17 (+1.50%)

SAVE Spirit Airlines
$12.96 /

+0.035 (+0.27%)

PSX Phillips 66
$78.30 /

-0.35 (-0.45%)

MSFT Microsoft
$183.30 /

+2.06 (+1.14%)

MPC Marathon Petroleum
$35.13 /

-0.08 (-0.23%)

LVS Las Vegas Sands
$47.96 /

-0.62 (-1.28%)

LUV Southwest
$32.11 /

-0.44 (-1.35%)

LIND Lindblad Expeditions
$7.87 /

+0.2 (+2.61%)

GOOG Alphabet
$1,430.80 /

+14.43 (+1.02%)

FB Facebook
$223.10 /

-2.04 (-0.91%)

DAL Delta Air Lines
$25.19 /

-0.47 (-1.83%)

CTRE CareTrust REIT
$18.62 /

-0.73 (-3.77%)

CQP Cheniere Energy Partners
$33.91 /

+0.87 (+2.63%)

COTY Coty
$3.63 /

-0.56 (-13.38%)

BAESY BAE Systems
$0.00 /

+ (+0.00%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

AAPL Apple
$317.94 /

-0.38 (-0.12%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

05/27/20 Morgan Stanley
Amazon deal could open door for ridesharing competition, says Morgan Stanley
05/18/20 Bernstein
Amazon not building standalone overnight network, says Bernstein
05/14/20 KeyBanc
Farfetch, Nordstrom, Revolve could be impacted by Amazon offering, says KeyBanc
05/12/20 Barrington
Amazon interest in AMC 'not outside the realm of possibility,' says Barrington
AAPL Apple
$317.94 /

-0.38 (-0.12%)

05/28/20 JPMorgan
Apple price target raised to $365 from $350 at JPMorgan
05/27/20 BofA
Apple price target raised to $340 from $320 at BofA
05/27/20 Jefferies
Apple price target raised to $370 from $350 at Jefferies
05/27/20 Deutsche Bank
Apple price target raised to $320 from $305 at Deutsche Bank
TGT Target
$122.50 /

+4.055 (+3.42%)

05/21/20 Deutsche Bank
Target price target raised to $131 from $121 at Deutsche Bank
05/21/20 Nomura Instinet
Target price target raised to $135 from $121 at Nomura Instinet
05/21/20 BMO Capital
Target price target raised to $135 from $125 at BMO Capital
05/21/20 Barclays
Target price target raised to $135 from $120 at Barclays
ALXN Alexion
$120.03 /

+5.595 (+4.89%)

05/28/20 Raymond James
Raymond James keeps Outperform on Alexion after IP settlement analysis
05/28/20 Piper Sandler
Alexion settlement could 'clear the deck' for acquirer, says Piper Sandler
05/28/20 Cowen
Alexion settlement may yield upside surprise, says Cowen
05/28/20 Stifel
Alexion, Amgen appear to have agreed to settlement deal, says Stifel
AMGN Amgen
$230.13 /

+6.11 (+2.73%)

05/22/20 Piper Sandler
Harpoon Therapeutics initiated with an Overweight at Piper Sandler
TWTR Twitter
$30.97 /

-0.63 (-1.99%)

05/29/20 Baird
Twitter, Facebook pullbacks would likely be buying opportunities, says Baird
05/29/20 JPMorgan
Trump order may put 'overhang' on big tech in coming months, says JPMorgan
05/27/20 Cowen
Cowen says Twitter 'will be fine,' but Republicans could support Facebook suit
05/06/20 China Renaissance
Twitter price target lowered to $23 from $25 at China Renaissance
MSFT Microsoft
$183.30 /

+2.06 (+1.14%)

05/28/20 Needham
Workday price target raised to $200 from $175 at Needham
05/27/20 Summit Insights
Microsoft initiated with a Buy at Summit Insights
05/18/20 RBC Capital
Microsoft price target raised to $200 from $196 at RBC Capital
05/15/20 Morgan Stanley
Security another large market opportunity for Microsoft, says Morgan Stanley
GOOG Alphabet
$1,430.80 /

+14.43 (+1.02%)

05/12/20 Citi
Alphabet price target raised to $1,600 from $1,400 at Citi
05/07/20 Credit Suisse
YouTube TV deal 'the big news' from ViacomCBS report, says Credit Suisse
GOOGL Alphabet Class A
$1,435.82 /

+17.61 (+1.24%)

FB Facebook
$223.10 /

-2.04 (-0.91%)

05/27/20 Citi
Facebook price target raised to $275 from $245 at Citi
COTY Coty
$3.63 /

-0.56 (-13.38%)

05/13/20 Exane BNP Paribas
Coty downgraded to Neutral from Outperform at Exane BNP Paribas
05/13/20 Exane BNP Paribas
Coty downgraded to Neutral from Outperform at Exane BNP Paribas
05/12/20 Deutsche Bank
Coty price target lowered to $6 from $8 at Deutsche Bank
04/27/20
Coty cut to Neutral at DA Davidson on valuation
SAVE Spirit Airlines
$12.96 /

+0.035 (+0.27%)

05/29/20 Wolfe Research
Spirit Airlines downgraded to Underperform from Peer Perform at Wolfe Research
05/18/20 Evercore ISI
Spirit Airlines upgraded to Outperform from In Line at Evercore ISI
05/13/20
Fly Intel: Top five analyst downgrades
05/13/20 Raymond James
Spirit Airlines downgraded to Market Perform from Outperform at Raymond James
LUV Southwest
$32.11 /

-0.44 (-1.35%)

05/26/20
Fly Intel: Top five analyst upgrades
05/26/20 UBS
Southwest upgraded to Buy from Neutral at UBS
05/19/20 Goldman Sachs
Southwest, United seeing modest improvements in demand, says Goldman Sachs
05/04/20 Barclays
Barclays downgrades U.S. Airlines sector along with American and Delta
DAL Delta Air Lines
$25.19 /

-0.47 (-1.83%)

05/04/20 Barclays
Delta Air Lines downgraded to Equal Weight from Overweight at Barclays
04/23/20 Raymond James
Delta Air Lines price target lowered to $36 from $40 at Raymond James
04/21/20 Deutsche Bank
Delta Air Lines price target lowered to $47 from $51 at Deutsche Bank
STAY Extended Stay America
$11.50 /

+0.17 (+1.50%)

04/22/20
Fly Intel: Top five analyst upgrades
04/22/20 BofA
Choice Hotels upgraded to Neutral from Underperform at Bofa
04/22/20 Jefferies
Jefferies upgrades Extended Stay America to Buy, doubles price target to $14
04/22/20 Jefferies
Extended Stay America upgraded to Buy from Hold at Jefferies
LIND Lindblad Expeditions
$7.87 /

+0.2 (+2.61%)

04/28/20 Stifel
Lindblad demand should return faster than 'normal' cruises, says Stifel
04/22/20 Deutsche Bank
Lindblad Expeditions price target lowered to $7 from $16 at Deutsche Bank
04/13/20 Sidoti
Lindblad Expeditions downgraded to Neutral from Buy at Sidoti
03/25/20 Sidoti
Lindblad Expeditions upgraded to Buy from Neutral at Sidoti
MPC Marathon Petroleum
$35.13 /

-0.08 (-0.23%)

05/13/20 Morgan Stanley
U.S. gasoline consumption appears to have bottomed, says Morgan Stanley
04/24/20 Citi
Marathon Petroleum downgraded to Neutral from Buy at Citi
03/24/20 Raymond James
Marathon Petroleum double downgraded to Market Perform at Raymond James
03/24/20 Raymond James
Marathon Petroleum downgraded to Market Perform from Strong Buy at Raymond James
LVS Las Vegas Sands
$47.96 /

-0.62 (-1.28%)

05/21/20
Fly Intel: Top five analyst upgrades
05/21/20 Credit Suisse
Credit Suisse upgrades Las Vegas Sands to Outperform with $58 target
05/21/20 Credit Suisse
Las Vegas Sands assumed with an Outperform from Neutral at Credit Suisse
05/06/20 Roth Capital
Las Vegas Sands price target lowered to $52 from $69 at Roth Capital
CTRE CareTrust REIT
$18.62 /

-0.73 (-3.77%)

04/29/20 Raymond James
CareTrust REIT upgraded to Outperform from Market Perform at Raymond James
04/29/20 Raymond James
CareTrust REIT upgraded to Outperform from Market Perform at Raymond James
04/06/20 Mizuho
CareTrust REIT upgraded to Neutral from Underperform at Mizuho
03/11/20 Mizuho
Sabra Health Care to be pressured by coronavirus at facility, says Mizuho
VLO Valero
$66.62 /

-0.59 (-0.88%)

05/21/20 US Capital Advisors
Valero downgraded to Overweight from Buy at US Capital Advisors
05/04/20 Mizuho
Mizuho upgrades Valero, Phillips 66 and HollyFrontier to Buy from Neutral
05/04/20 Mizuho
Valero upgraded to Buy from Neutral at Mizuho
PSX Phillips 66
$78.30 /

-0.35 (-0.45%)

05/21/20 US Capital Advisors
Phillips 66 downgraded to Overweight from Buy at US Capital Advisors
05/13/20 Wolfe Research
Phillips 66 downgraded to Peer Perform from Outperform at Wolfe Research
CQP Cheniere Energy Partners
$33.91 /

+0.87 (+2.63%)

03/24/20 Barclays
Cheniere Energy Partners upgraded to Overweight from Equal Weight at Barclays
03/12/20 Credit Suisse
Cheniere Energy Partners upgraded to Neutral from Underperform at Credit Suisse
03/05/20 UBS
Cheniere Energy Partners upgraded to Buy from Neutral at UBS
02/26/20 Odeon Capital
Cheniere Energy Partners upgraded to Buy from Hold at Odeon Capital
BAESY BAE Systems
$0.00 /

+ (+0.00%)

05/18/20 UBS
BAE Systems price target lowered to 511 GBp from 700 GBp at UBS
04/29/20 JPMorgan
BAE Systems price target lowered to 765 GBp from 775 GBp at JPMorgan
04/29/20 JPMorgan
BAE Systems shares offer 50% upside potential, says JPMorgan
04/27/20 Morgan Stanley
BAE Systems upgraded to Overweight from Equal Weight at Morgan Stanley
VLO Valero
$66.62 /

-0.59 (-0.88%)

TWTR Twitter
$30.97 /

-0.63 (-1.99%)

TGT Target
$122.50 /

+4.055 (+3.42%)

STAY Extended Stay America
$11.50 /

+0.17 (+1.50%)

SAVE Spirit Airlines
$12.96 /

+0.035 (+0.27%)

PSX Phillips 66
$78.30 /

-0.35 (-0.45%)

MSFT Microsoft
$183.30 /

+2.06 (+1.14%)

MPC Marathon Petroleum
$35.13 /

-0.08 (-0.23%)

LVS Las Vegas Sands
$47.96 /

-0.62 (-1.28%)

LUV Southwest
$32.11 /

-0.44 (-1.35%)

LIND Lindblad Expeditions
$7.87 /

+0.2 (+2.61%)

GOOG Alphabet
$1,430.80 /

+14.43 (+1.02%)

FB Facebook
$223.10 /

-2.04 (-0.91%)

DAL Delta Air Lines
$25.19 /

-0.47 (-1.83%)

CTRE CareTrust REIT
$18.62 /

-0.73 (-3.77%)

CQP Cheniere Energy Partners
$33.91 /

+0.87 (+2.63%)

COTY Coty
$3.63 /

-0.56 (-13.38%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

AAPL Apple
$317.94 /

-0.38 (-0.12%)

VLO Valero
$66.62 /

-0.59 (-0.88%)

TWTR Twitter
$30.97 /

-0.63 (-1.99%)

TGT Target
$122.50 /

+4.055 (+3.42%)

STAY Extended Stay America
$11.50 /

+0.17 (+1.50%)

SAVE Spirit Airlines
$12.96 /

+0.035 (+0.27%)

PSX Phillips 66
$78.30 /

-0.35 (-0.45%)

MSFT Microsoft
$183.30 /

+2.06 (+1.14%)

MPC Marathon Petroleum
$35.13 /

-0.08 (-0.23%)

LVS Las Vegas Sands
$47.96 /

-0.62 (-1.28%)

LUV Southwest
$32.11 /

-0.44 (-1.35%)

LIND Lindblad Expeditions
$7.87 /

+0.2 (+2.61%)

GOOG Alphabet
$1,430.80 /

+14.43 (+1.02%)

CTRE CareTrust REIT
$18.62 /

-0.73 (-3.77%)

CQP Cheniere Energy Partners
$33.91 /

+0.87 (+2.63%)

COTY Coty
$3.63 /

-0.56 (-13.38%)

BAESY BAE Systems
$0.00 /

+ (+0.00%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

AAPL Apple
$317.94 /

-0.38 (-0.12%)

TWTR Twitter
$30.97 /

-0.63 (-1.99%)

TGT Target
$122.50 /

+4.055 (+3.42%)

STAY Extended Stay America
$11.50 /

+0.17 (+1.50%)

SAVE Spirit Airlines
$12.96 /

+0.035 (+0.27%)

MSFT Microsoft
$183.30 /

+2.06 (+1.14%)

MPC Marathon Petroleum
$35.13 /

-0.08 (-0.23%)

LVS Las Vegas Sands
$47.96 /

-0.62 (-1.28%)

LUV Southwest
$32.11 /

-0.44 (-1.35%)

DAL Delta Air Lines
$25.19 /

-0.47 (-1.83%)

CQP Cheniere Energy Partners
$33.91 /

+0.87 (+2.63%)

COTY Coty
$3.63 /

-0.56 (-13.38%)

BAESY BAE Systems
$0.00 /

+ (+0.00%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

AAPL Apple
$317.94 /

-0.38 (-0.12%)

VLO Valero
$66.62 /

-0.59 (-0.88%)

TWTR Twitter
$30.97 /

-0.63 (-1.99%)

TGT Target
$122.50 /

+4.055 (+3.42%)

SAVE Spirit Airlines
$12.96 /

+0.035 (+0.27%)

PSX Phillips 66
$78.30 /

-0.35 (-0.45%)

MSFT Microsoft
$183.30 /

+2.06 (+1.14%)

MPC Marathon Petroleum
$35.13 /

-0.08 (-0.23%)

LVS Las Vegas Sands
$47.96 /

-0.62 (-1.28%)

LUV Southwest
$32.11 /

-0.44 (-1.35%)

GOOGL Alphabet Class A
$1,435.82 /

+17.61 (+1.24%)

GOOG Alphabet
$1,430.80 /

+14.43 (+1.02%)

FB Facebook
$223.10 /

-2.04 (-0.91%)

DAL Delta Air Lines
$25.19 /

-0.47 (-1.83%)

COTY Coty
$3.63 /

-0.56 (-13.38%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

AAPL Apple
$317.94 /

-0.38 (-0.12%)

GOOG Alphabet
$1,430.80 /

+14.43 (+1.02%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AAPL Apple
$317.94 /

-0.38 (-0.12%)

Upgrade
Standard Chartered upgraded to Buy from Underperform at Jefferies » 20:14
05/31/20
05/31
20:14
05/31/20
20:14
SCBFF

Standard Chartered

$0.00 /

+ (+0.00%)

, HSBC

HSBC

$23.06 /

-0.555 (-2.35%)

Jefferies analyst Joseph…

Jefferies analyst Joseph Dickerson double upgraded Standard Chartered (SCBFF) to Buy from Underperform with a price target of 575 GBp, up from 438 GBp. The analyst says that while near-term headline risk on Hong Kong is very likely to remain negative, he's constructive on the medium-term fundamentals. Dickerson views Standard Chartered's trading multiple as "depressed" and sees upside to consensus expectations. The analyst coupled the upgrade with a downgrade of HSBC (HSBC) to Hold.

ShowHide Related Items >><<
SCBFF Standard Chartered
$0.00 /

+ (+0.00%)

HSBC HSBC
$23.06 /

-0.555 (-2.35%)

SCBFF Standard Chartered
$0.00 /

+ (+0.00%)

05/21/20 Exane BNP Paribas
Standard Chartered upgraded to Neutral from Underperform at Exane BNP Paribas
03/17/20 HSBC
Standard Chartered upgraded to Hold from Reduce at HSBC
03/16/20 Citi
Standard Chartered upgraded to Buy from Neutral at Citi
11/15/19 Exane BNP Paribas
Standard Chartered downgraded to Underperform from Neutral at Exane BNP Paribas
HSBC HSBC
$23.06 /

-0.555 (-2.35%)

05/31/20 Jefferies
HSBC downgraded to Hold from Buy at Jefferies
05/14/20 Berenberg
HSBC upgraded to Hold from Sell at Berenberg
05/12/20 RBC Capital
HSBC price target lowered to 410 GBp from 440 GBp at RBC Capital
05/05/20 Barclays
HSBC price target lowered to 410 GBp from 420 GBp at Barclays
HSBC HSBC
$23.06 /

-0.555 (-2.35%)

SCBFF Standard Chartered
$0.00 /

+ (+0.00%)

HSBC HSBC
$23.06 /

-0.555 (-2.35%)

HSBC HSBC
$23.06 /

-0.555 (-2.35%)

HSBC HSBC
$23.06 /

-0.555 (-2.35%)

Periodicals
Coty to appoint Chairman Peter Harf as new CEO, WSJ reports » 20:14
05/31/20
05/31
20:14
05/31/20
20:14
COTY

Coty

$3.63 /

-0.56 (-13.38%)

Coty is set to appoint…

Coty is set to appoint its fourth new chief executive in less than four years, as the cosmetics and fragrance maker strives to revive slumping sales and reduce its burdensome debt load, The Wall Street Journal's Ben Dummett and Sharon Terlep report. Peter Harf, Coty's current chairman, will also assume the CEO role as soon as Monday, the authors noted, citing people familiar with the matter. Reference Link

ShowHide Related Items >><<
COTY Coty
$3.63 /

-0.56 (-13.38%)

COTY Coty
$3.63 /

-0.56 (-13.38%)

05/13/20 Exane BNP Paribas
Coty downgraded to Neutral from Outperform at Exane BNP Paribas
05/13/20 Exane BNP Paribas
Coty downgraded to Neutral from Outperform at Exane BNP Paribas
05/12/20 Deutsche Bank
Coty price target lowered to $6 from $8 at Deutsche Bank
04/27/20
Coty cut to Neutral at DA Davidson on valuation
COTY Coty
$3.63 /

-0.56 (-13.38%)

COTY Coty
$3.63 /

-0.56 (-13.38%)

COTY Coty
$3.63 /

-0.56 (-13.38%)

COTY Coty
$3.63 /

-0.56 (-13.38%)

Hot Stocks
Immutep reports first results from INSIGHT-004 study » 20:11
05/31/20
05/31
20:11
05/31/20
20:11
IMMP

Immutep

$1.25 /

+0.005 (+0.40%)

, MRK

Merck

$80.85 /

+1.83 (+2.32%)

, PFE

Pfizer

$38.14 /

-0.03 (-0.08%)

Immutep (IMMP) has…

Immutep (IMMP) has reported first interim data from its ongoing INSIGHT-004 Phase I clinical trial. The study is a phase I trial evaluating the combination of Immutep's lead product candidate, eftilagimod alpha with avelumab, a human anti-PD-L1 antibody, in 12 patients with solid cancers. Avelumab is co-developed and co-commercialized by Merck (MRK) KGaA, Darmstadt, Germany and Pfizer (PFE). The data was reported in a short talk poster presentation at the virtual event for the 2020 American Society of Clinical Oncology's Annual Meeting. INSIGHT-004 is the fourth arm of the investigator-initiated INSIGHT trial which is being conducted by the Institute of Clinical Cancer Research IKF at Krankenhaus Nordwest in Frankfurt. It is being conducted under Immutep's collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer, and is evaluating the safety, tolerability and recommended Phase II dose of efti when given in combination with avelumab. Patients in cohort 1 receive 6mg doses of efti every two weeks with the standard dose of avelumab, while patients in cohort 2 receive a higher dose of efti, 30mg, with avelumab. INSIGHT-004 reached full recruitment in April 2020 and has recruited patients in different solid tumors, primarily with gastrointestinal indications. It is the first combination trial of an approved and marketed anti-PD-L1 drug and efti. Salah-Eddin Al-Batran, INSIGHT-004 trial investigator and Director of Oncology at IKF said: "It is good to see a number of patients are responding to the combination therapy of efti and avelumab, particularly as three patients in cohort 2 are still very early on in their treatment and haven't yet been assessed. INSIGHT-004 is progressing well and we are pleased that efti continues to be safe and well tolerated by patients. These patients typically are heavily pretreated and do not have any good therapy options."

ShowHide Related Items >><<
PFE Pfizer
$38.14 /

-0.03 (-0.08%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

IMMP Immutep
$1.25 /

+0.005 (+0.40%)

IMMP Immutep
$1.25 /

+0.005 (+0.40%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

05/27/20 Alliance Global Partners
PDS Biotechnology initiated with a Buy at Alliance Global Partners
05/20/20 JonesTrading
Merck collaboration positions Surface Oncology well, says JonesTrading
04/27/20 SVB Leerink
Clovis downgraded to Underperform at SVB Leerink as prostate opportunity fades
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
PFE Pfizer
$38.14 /

-0.03 (-0.08%)

05/21/20 Piper Sandler
Gilead's filgotinib likely being underestimated by Street, says Piper Sandler
05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Goldman Sachs
After Pfizer data, Goldman says Sarepta remains 'leader' in DMD gene therapy
05/15/20 JPMorgan
JPMorgan still sees Sarepta in pole position in DMD space
PFE Pfizer
$38.14 /

-0.03 (-0.08%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

Hot Stocks
Immutep announces data from Phase II TACTI-002 study » 20:08
05/31/20
05/31
20:08
05/31/20
20:08
IMMP

Immutep

$1.25 /

+0.005 (+0.40%)

, MRK

Merck

$80.85 /

+1.83 (+2.32%)

Immutep (IMMP) announced…

Immutep (IMMP) announced new interim data from its ongoing Phase II TACTI-002 study. This data relates to the cut-off date of 4 May 2020 and shows "improving efficacy results," the company said. The results were presented as a poster short talk at the 2020 American Society of Clinical Oncology Virtual Annual Meeting. TACTI-002 is being conducted in collaboration with Merck (MRK). The study is evaluating the combination of the company's lead product candidate eftilagimod alpha with Merck's KEYTRUDA in up to 109 patients with second line Head and Neck Squamous Cell Carcinoma or Non-Small Cell Lung Cancer in first and second line. Immutep CSO and CMO, Frederic Triebel said: "TACTI-002 is generating increasingly promising data from both the NSCLC and HNSCC arms of study, as patients continue to receive efti in combination with KEYTRUDA. Remarkably, one HNSCC patient has even achieved a complete response, bringing the total response rate to an improved 39% in this arm. This is an early indication that the efti in combination with pembrolizumab may more than double the proportion of HNSCC patients that respond to pembrolizumab monotherapy, which is usually 18% or less1."

ShowHide Related Items >><<
MRK Merck
$80.85 /

+1.83 (+2.32%)

IMMP Immutep
$1.25 /

+0.005 (+0.40%)

IMMP Immutep
$1.25 /

+0.005 (+0.40%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

05/27/20 Alliance Global Partners
PDS Biotechnology initiated with a Buy at Alliance Global Partners
05/20/20 JonesTrading
Merck collaboration positions Surface Oncology well, says JonesTrading
04/27/20 SVB Leerink
Clovis downgraded to Underperform at SVB Leerink as prostate opportunity fades
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
MRK Merck
$80.85 /

+1.83 (+2.32%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

Hot Stocks
Innovent Biologics, Eli Lilly announce follow-up results of TYVYT ORIENT-1 study » 20:05
05/31/20
05/31
20:05
05/31/20
20:05
LLY

Eli Lilly

$153.14 /

+2.51 (+1.67%)

Innovent Biologics…

Innovent Biologics jointly announced with Eli Lilly the research results of TYVYT ORIENT-1 study for the treatment of relapsed or refractory classic Hodgkin's lymphoma, at the 56th Annual Meeting of the American Society of Clinical Oncology. The ORIENT-1 study is a multicenter, single-arm, Phase 2 clinical trial, assessing the efficacy and safety of sintilimab in r/r cHL. Subjects received 200 mg of sintilimab every three weeks in this study until disease progression. A total of 96 subjects with r/r cHL were enrolled, and the study's primary endpoint was objective response rate assessed by an independent imaging assessment committee. In addition, the complete response rate was a secondary endpoint in the ORIENT-1 study. As of the data cutoff on September 30, 2019, the ORR was 85.4% based on IRRC review, of which 41 patients achieved complete response.

ShowHide Related Items >><<
LLY Eli Lilly
$153.14 /

+2.51 (+1.67%)

LLY Eli Lilly
$153.14 /

+2.51 (+1.67%)

05/29/20 Raymond James
Blueprint approval for pralsetinib could come before PDUFA, says Raymond James
04/24/20 Cantor Fitzgerald
Eli Lilly price target raised to $185 from $156 at Cantor Fitzgerald
04/24/20 Mizuho
Eli Lilly price target raised to $155 from $148 at Mizuho
04/21/20
Fly Intel: Top five analyst downgrades
LLY Eli Lilly
$153.14 /

+2.51 (+1.67%)

LLY Eli Lilly
$153.14 /

+2.51 (+1.67%)

LLY Eli Lilly
$153.14 /

+2.51 (+1.67%)

Hot Stocks
Innovent Biologics, Eli Lilly announce results of TYVYT ORIENT-2 study » 20:01
05/31/20
05/31
20:01
05/31/20
20:01
LLY

Eli Lilly

$153.14 /

+2.51 (+1.67%)

Innovent Biologics…

Innovent Biologics jointly announced with Eli Lilly the results of TYVYT ORIENT-2 study, a pivotal clinical study of second-line treatment for locally advanced or metastatic esophageal squamous cell carcinoma at the 56th Annual Meeting of the American Society of Clinical Oncology. The ORIENT-2 study was a randomized, open-label, multicenter, Phase 2 clinical study comparing the efficacy and safety of sintilimab with chemotherapy in patients with advanced or metastatic ESCC whose disease progressed on first-line therapy. A total of 190 subjects were enrolled in the study and randomly assigned in a 1:1 ratio to receive either sintilimab injection or chemotherapy. The study's primary endpoint was overall survival. As of August 2, 2019, compared with paclitaxel/irinotecan, sintilimab demonstrated a statistically significant improvement in OS in the intent-to-treat population. The median OS in the sintilimab-treated group and the chemotherapy-treated group were 7.2 months and 6.2 months and the 12-month OS rates were 37.4% and 21.4%, respectively, showing "encouraging" antitumor efficacy in the sintilimab-treated group, the companies said. The safety profile of sintilimab in this study of ESCC patients was similar to that seen in studies of sintilimab in other tumors.

ShowHide Related Items >><<
LLY Eli Lilly
$153.14 /

+2.51 (+1.67%)

LLY Eli Lilly
$153.14 /

+2.51 (+1.67%)

05/29/20 Raymond James
Blueprint approval for pralsetinib could come before PDUFA, says Raymond James
04/24/20 Cantor Fitzgerald
Eli Lilly price target raised to $185 from $156 at Cantor Fitzgerald
04/24/20 Mizuho
Eli Lilly price target raised to $155 from $148 at Mizuho
04/21/20
Fly Intel: Top five analyst downgrades
LLY Eli Lilly
$153.14 /

+2.51 (+1.67%)

LLY Eli Lilly
$153.14 /

+2.51 (+1.67%)

LLY Eli Lilly
$153.14 /

+2.51 (+1.67%)

Initiation
Xenon Pharmaceuticals assumed with a Buy at Jefferies » 19:57
05/31/20
05/31
19:57
05/31/20
19:57
XENE

Xenon Pharmaceuticals

$13.99 /

+1.36 (+10.77%)

Jefferies analyst Andrew…

Jefferies analyst Andrew Tsai assumed coverage of Xenon Pharmaceuticals with a Buy rating with a price target of $23, up from $16. The analyst believes that Phase IIb data in the first half of 2021 for XEN1101 in broad seizures has a 50% chance to push the stock up 50%-75%. Tsai also thinks Phase III-ready XEN496 for rare pediatric epilepsy has a similar chance of success.

ShowHide Related Items >><<
XENE Xenon Pharmaceuticals
$13.99 /

+1.36 (+10.77%)

XENE Xenon Pharmaceuticals
$13.99 /

+1.36 (+10.77%)

03/25/20
Fly Intel: Top five analyst initiations
03/24/20 Wedbush
Xenon Pharmaceuticals initiated with an Outperform at Wedbush
03/24/20 Wedbush
Xenon Pharmaceuticals initiated with an Outperform at Wedbush
01/08/20 William Blair
Xenon Pharmaceuticals initiated with an Outperform at William Blair
XENE Xenon Pharmaceuticals
$13.99 /

+1.36 (+10.77%)

Downgrade
HSBC downgraded to Hold from Buy at Jefferies » 19:55
05/31/20
05/31
19:55
05/31/20
19:55
HSBC

HSBC

$23.06 /

-0.555 (-2.35%)

Jefferies analyst Joseph…

Jefferies analyst Joseph Dickerson downgraded HSBC to Hold from Buy with a price target of 400 GBp, down from 790 GBp. The analyst believes that against higher execution risk, the 8% upside to his price target is not enough to justify a Buy, nor is the risk/reward set-up attractive.

ShowHide Related Items >><<
HSBC HSBC
$23.06 /

-0.555 (-2.35%)

HSBC HSBC
$23.06 /

-0.555 (-2.35%)

05/14/20 Berenberg
HSBC upgraded to Hold from Sell at Berenberg
05/12/20 RBC Capital
HSBC price target lowered to 410 GBp from 440 GBp at RBC Capital
05/05/20 Barclays
HSBC price target lowered to 410 GBp from 420 GBp at Barclays
04/29/20 UBS
HSBC price target lowered to 405 GBp from 450 GBp at UBS
HSBC HSBC
$23.06 /

-0.555 (-2.35%)

HSBC HSBC
$23.06 /

-0.555 (-2.35%)

HSBC HSBC
$23.06 /

-0.555 (-2.35%)

HSBC HSBC
$23.06 /

-0.555 (-2.35%)

Initiation
Becton Dickinson initiated with a Buy at Goldman Sachs » 18:38
05/31/20
05/31
18:38
05/31/20
18:38
BDX

Becton Dickinson

$246.97 /

+5.47 (+2.27%)

Goldman Sachs analyst…

Goldman Sachs analyst Amit Hazan initiated coverage of Becton Dickinson with a Buy rating and $278 price target. During this period of uncertainty, Becton is one of the more attractive investments in Medical Technology, Hazan tells investors in a research note. The analyst sees "relative top-line durability" and potential for sales upside from "COVID related tailwinds" next fiscal year. Further, the shares are attractively value compared to "other so called medtech safe-havens," says Hazan.

ShowHide Related Items >><<
BDX Becton Dickinson
$246.97 /

+5.47 (+2.27%)

BDX Becton Dickinson
$246.97 /

+5.47 (+2.27%)

05/14/20 Piper Sandler
Becton Dickinson price target raised to $296 from $286 at Piper Sandler
04/08/20 Wells Fargo
Becton Dickinson price target lowered to $270 from $279 at Wells Fargo
03/04/20 Citi
Becton Dickinson initiated with a Neutral at Citi
03/02/20 Wells Fargo
Baxter, J&J best positioned to weather coronavirus spread, says Wells Fargo
BDX Becton Dickinson
$246.97 /

+5.47 (+2.27%)

BDX Becton Dickinson
$246.97 /

+5.47 (+2.27%)

BDX Becton Dickinson
$246.97 /

+5.47 (+2.27%)

Downgrade
Abbott downgraded to Sell from Neutral at Goldman Sachs » 18:32
05/31/20
05/31
18:32
05/31/20
18:32
ABT

Abbott

$95.31 /

+3.23 (+3.51%)

Goldman Sachs analyst…

Goldman Sachs analyst Amit Hazan downgraded Abbott Laboratories to Sell from Neutral with a price target of $84, up from $79. The shares closed Friday up $2.82 to $94.95. The stock has overreacted to the company's COVID testing opportunity, Hazan tells investors in a research note. Despite taking an early lead with multiple viral and antibody emergency use authorizations in the U.S. and a "sizable" test production outlook, competitors have steadily diminished Abbott's early advantage with their own approvals on high throughput systems, says the analyst. Hazan sees 10% downside in the shares and remains skeptical that the demand for antibody testing will reach a material level for Abbott revenues given the much lower price point for those tests.

ShowHide Related Items >><<
ABT Abbott
$95.31 /

+3.23 (+3.51%)

ABT Abbott
$95.31 /

+3.23 (+3.51%)

04/20/20 Barclays
Abbott price target raised to $100 from $92 at Barclays
04/20/20 Barclays
Abbott price target raised to $100 from $92 at Barclays
04/17/20 Raymond James
Abbott price target raised to $102 from $92 at Raymond James
04/17/20 Credit Suisse
Abbott price target raised to $106 from $95 at Credit Suisse
ABT Abbott
$95.31 /

+3.23 (+3.51%)

ABT Abbott
$95.31 /

+3.23 (+3.51%)

ABT Abbott
$95.31 /

+3.23 (+3.51%)

ABT Abbott
$95.31 /

+3.23 (+3.51%)

Recommendations
Pebblebrook Hotel price target raised to $13 from $11 at Stifel » 18:21
05/31/20
05/31
18:21
05/31/20
18:21
PEB

Pebblebrook Hotel

$13.66 /

-0.44 (-3.12%)

Stifel analyst Simon…

Stifel analyst Simon Yarmak raised the firm's price target on Pebblebrook Hotel to $13 from $11 and keeps a Hold rating on the shares. The company's sale of the 125-room Union Station Hotel Nashville for $56M improves its liquidity position, Yarmak tells investors in a research note. The analyst adds that this is the first real estate investment trust hotel put under contract since the pandemic hit in early March.

ShowHide Related Items >><<
PEB Pebblebrook Hotel
$13.66 /

-0.44 (-3.12%)

PEB Pebblebrook Hotel
$13.66 /

-0.44 (-3.12%)

04/24/20 BTIG
Pebblebrook Hotel, Host Hotesl upgraded to Buy from Neutral at BTIG
04/24/20 BTIG
Pebblebrook Hotel upgraded to Buy from Neutral at BTIG
04/07/20 Citi
Pebblebrook Hotel downgraded to Sell from Neutral at Citi
03/17/20 Stifel
Pebblebrook Hotel downgraded to Hold from Buy at Stifel
PEB Pebblebrook Hotel
$13.66 /

-0.44 (-3.12%)

PEB Pebblebrook Hotel
$13.66 /

-0.44 (-3.12%)

Hot Stocks
Alexion, Amgen reach settlement deal on patent challenge » 16:37
05/31/20
05/31
16:37
05/31/20
16:37
ALXN

Alexion

$120.03 /

+5.595 (+4.89%)

, AMGN

Amgen

$230.13 /

+6.11 (+2.73%)

According to a…

According to a company's filing, "On May 28, 2020, Alexion Pharmaceuticals [ALXN] and Amgen [AMGN] entered into a Confidential Settlement and License Agreement to settle three inter partes review proceedings at the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office initiated by Amgen that the Company previously disclosed. Pursuant to the Settlement Agreement, the company and Amgen have agreed to file a motion with the PTAB to terminate each of the pending IPRs. In addition, effective March 1, 2025 (or an earlier date in certain circumstances), the company grants to Amgen (and its affiliates and certain partners) a non-exclusive, royalty-free, license under U.S. patents and patent applications related to eculizumab and various aspects of the eculizumab product that the company currently markets and sells under the tradename SOLIRIS. This license will allow Amgen (and its affiliates and certain partners), effective March 1, 2025, the right to make, have made, use, import, have imported, sell, have sold, offer for sale, have offered for sale, distribute, and have distributed in or for the U.S., an eculizumab product." The foregoing description of the Settlement Agreement does not purport to be complete and is qualified in its entirety by reference to the Settlement Agreement, which the Company intends to file as an exhibit to a future current or periodic report.

ShowHide Related Items >><<
AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

05/28/20 Raymond James
Raymond James keeps Outperform on Alexion after IP settlement analysis
05/28/20 Piper Sandler
Alexion settlement could 'clear the deck' for acquirer, says Piper Sandler
05/28/20 Cowen
Alexion settlement may yield upside surprise, says Cowen
05/28/20 Stifel
Alexion, Amgen appear to have agreed to settlement deal, says Stifel
AMGN Amgen
$230.13 /

+6.11 (+2.73%)

05/22/20 Piper Sandler
Harpoon Therapeutics initiated with an Overweight at Piper Sandler
AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

ALXN Alexion
$120.03 /

+5.595 (+4.89%)

Periodicals
Amazon curbs operations, Apple keeps some stores closed, Bloomberg says » 16:22
05/31/20
05/31
16:22
05/31/20
16:22
AMZN

Amazon.com

$2,442.37 /

+42.04 (+1.75%)

, AAPL

Apple

$317.94 /

-0.38 (-0.12%)

, TGT

Target

$122.50 /

+4.055 (+3.42%)

Amazon (AMZN) scaled back…

Amazon (AMZN) scaled back deliveries and adjusted routes in cities including Chicago and Los Angeles, Apple (APPL) kept some outlets shut, while Target (TGT) extended store closures nationwide after the death of George Floyd sparked demonstrations across the country, Bloomberg's Spencer Soper and James Ludden report. "We are monitoring the situation closely and in a handful of cities we adjusted routes or scaled back typical operations to ensure the safety of our teams," an Amazon spokeswoman told Bloomberg News. Reference Link

ShowHide Related Items >><<
TGT Target
$122.50 /

+4.055 (+3.42%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AAPL Apple
$317.94 /

-0.38 (-0.12%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

05/27/20 Morgan Stanley
Amazon deal could open door for ridesharing competition, says Morgan Stanley
05/18/20 Bernstein
Amazon not building standalone overnight network, says Bernstein
05/14/20 KeyBanc
Farfetch, Nordstrom, Revolve could be impacted by Amazon offering, says KeyBanc
05/12/20 Barrington
Amazon interest in AMC 'not outside the realm of possibility,' says Barrington
AAPL Apple
$317.94 /

-0.38 (-0.12%)

05/28/20 JPMorgan
Apple price target raised to $365 from $350 at JPMorgan
05/27/20 BofA
Apple price target raised to $340 from $320 at BofA
05/27/20 Jefferies
Apple price target raised to $370 from $350 at Jefferies
05/27/20 Deutsche Bank
Apple price target raised to $320 from $305 at Deutsche Bank
TGT Target
$122.50 /

+4.055 (+3.42%)

05/21/20 Deutsche Bank
Target price target raised to $131 from $121 at Deutsche Bank
05/21/20 Nomura Instinet
Target price target raised to $135 from $121 at Nomura Instinet
05/21/20 BMO Capital
Target price target raised to $135 from $125 at BMO Capital
05/21/20 Barclays
Target price target raised to $135 from $120 at Barclays
TGT Target
$122.50 /

+4.055 (+3.42%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AAPL Apple
$317.94 /

-0.38 (-0.12%)

TGT Target
$122.50 /

+4.055 (+3.42%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AAPL Apple
$317.94 /

-0.38 (-0.12%)

TGT Target
$122.50 /

+4.055 (+3.42%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AAPL Apple
$317.94 /

-0.38 (-0.12%)

TGT Target
$122.50 /

+4.055 (+3.42%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AAPL Apple
$317.94 /

-0.38 (-0.12%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AAPL Apple
$317.94 /

-0.38 (-0.12%)

Hot Stocks
BioMarin provides update from Phase 1/2 study of Valoctocogene Roxaparvovec » 16:18
05/31/20
05/31
16:18
05/31/20
16:18
BMRN

BioMarin

$106.67 /

+1.1 (+1.04%)

BioMarin Pharmaceutical…

BioMarin Pharmaceutical announced an update to its previously reported results of an open-label Phase 1/2 study of valoctocogene roxaparvovec, an investigational gene therapy treatment for adults with severe hemophilia A. The data have been submitted as a late-breaking abstract to the World Federation of Hemophilia Virtual Summit to be held June 14-19, 2020. The four-year update for the 6e13 vg/kg and three-year update for the 4e13 vg/kg cohorts demonstrated that all subjects in both cohorts remain off prophylactic Factor VIII treatment since receiving their single dose of valoctocogene roxaparvovec. Cumulative mean annualized bleed rates remain less than one in both cohorts and below pre-treatment baseline levels. The mean ABR in year four for the 6e13 vg/kg cohort was 1.3, and the mean ABR in year three for the 4e13 vg/kg cohort was 0.5. Over the past year, six of the seven participants in the 6e13 vg/kg cohort and five of the six participants in the 4e13 vg/kg cohort remain free of spontaneous bleeds. Factor VIII activity levels declined commensurate with the most recent years' observations and remain in a range to provide hemostatic efficacy. Overall, the safety profile of valoctocogene roxaparvovec remains consistent with previously reported data with no delayed-onset treatment related events. No participants developed inhibitors to Factor VIII, and no participants withdrew from the study. No participants have developed thrombotic events. The most common adverse events associated with valoctocogene roxaparvovec occurred early and included transient infusion-associated reactions and transient, asymptomatic, and mild to moderate rise in the levels of certain proteins and enzymes measured in liver function tests with no long-lasting clinical sequelae. The Food and Drug Administration is reviewing the biologics license application, under Priority Review, for valoctocogene roxaparvovec with a PDUFA action date of August 21, 2020. The FDA also granted valoctocogene roxaparvovec Breakthrough Therapy designation. The European Medicines Agency validated the company's Marketing Authorization Application for valoctocogene roxaparvovec which has been in review under accelerated assessment since January. Recognizing valoctocogene roxaparvovec for its potential to benefit patients with unmet medical needs, EMA granted access to its Priority Medicines regulatory initiative. Although the MAA remains under accelerated assessment at this time, the company expects the review procedure to be extended by at least three months due to COVID-19 delays. Further, the company believes there is a high possibility that the MAA will revert to the standard review procedure, as is the case with most filings that initially receive accelerated assessment. Because of the combination of these events, the company expects an opinion from the Committee for Medicinal Products for Human Use in late 2020/early 2021. BioMarin's valoctocogene roxaparvovec has also received orphan drug designation from the FDA and EMA for the treatment of severe hemophilia A. The Orphan Drug Designation program is intended to advance the evaluation and development of products that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions.

ShowHide Related Items >><<
BMRN BioMarin
$106.67 /

+1.1 (+1.04%)

BMRN BioMarin
$106.67 /

+1.1 (+1.04%)

05/27/20 Citi
BioMarin a good takeout candidate, but not by Sanofi, says Citi
05/26/20 RBC Capital
BioMarin among Sanofi's most intriguing potential targets, says RBC Capital
05/22/20 Jefferies
Jefferies adds six names to Franchise Picks list, including BioMarin and TJX
05/08/20 Canaccord
BioMarin price target raised to $119 from $108 at Canaccord
BMRN BioMarin
$106.67 /

+1.1 (+1.04%)

BMRN BioMarin
$106.67 /

+1.1 (+1.04%)

BMRN BioMarin
$106.67 /

+1.1 (+1.04%)

Periodicals
Nike releases 'Don't Do it' ad after George Floyd death, NY Post reports » 15:39
05/31/20
05/31
15:39
05/31/20
15:39
NKE

Nike

$98.47 /

+0.52 (+0.53%)

Nike is telling its fans…

Nike is telling its fans "Don't Do It" as a public service announcement tackling racism in the wake of the death of George Floyd, which has led to protests throughout the country, The New York Post's Adam Schrader reports. "For once, Don't do It. Don't pretend there's not a problem in America. Don't turn your back on racism. Don't accept innocent lives being taken from us. Don't make any more excuses. Don't think this doesn't affect you. Don't sit back and be silent," reads the all-text post, featuring white letters on a black background. Reference Link

ShowHide Related Items >><<
NKE Nike
$98.47 /

+0.52 (+0.53%)

NKE Nike
$98.47 /

+0.52 (+0.53%)

04/28/20 BTIG
Nike initiated with a Buy at BTIG
04/28/20 Piper Sandler
Nike estimates lowered after Adidas results at Piper Sandler
04/14/20 OTR Global
Nike cancels some orders for low-priority retailers, says OTR Global
04/08/20 Piper Sandler
Piper lays out winners and losers in survey of 5,200 teens
NKE Nike
$98.47 /

+0.52 (+0.53%)

NKE Nike
$98.47 /

+0.52 (+0.53%)

NKE Nike
$98.47 /

+0.52 (+0.53%)

NKE Nike
$98.47 /

+0.52 (+0.53%)

Periodicals
Amazon removes racist messages on some product listings, Reuters reports » 13:46
05/31/20
05/31
13:46
05/31/20
13:46
AMZN

Amazon.com

$2,442.37 /

+42.04 (+1.75%)

, AAPL

Apple

$317.94 /

-0.38 (-0.12%)

Amazon (AMZN) said it was…

Amazon (AMZN) said it was removing certain images after messages using extremely strong racist abuse appeared on some listings on its U.K. website when users searched for Apple's (AAPL) AirPods and other similar products, according to Reuters. Reference Link

ShowHide Related Items >><<
AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AAPL Apple
$317.94 /

-0.38 (-0.12%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

05/27/20 Morgan Stanley
Amazon deal could open door for ridesharing competition, says Morgan Stanley
05/18/20 Bernstein
Amazon not building standalone overnight network, says Bernstein
05/14/20 KeyBanc
Farfetch, Nordstrom, Revolve could be impacted by Amazon offering, says KeyBanc
05/12/20 Barrington
Amazon interest in AMC 'not outside the realm of possibility,' says Barrington
AAPL Apple
$317.94 /

-0.38 (-0.12%)

05/28/20 JPMorgan
Apple price target raised to $365 from $350 at JPMorgan
05/27/20 BofA
Apple price target raised to $340 from $320 at BofA
05/27/20 Jefferies
Apple price target raised to $370 from $350 at Jefferies
05/27/20 Deutsche Bank
Apple price target raised to $320 from $305 at Deutsche Bank
AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AAPL Apple
$317.94 /

-0.38 (-0.12%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AAPL Apple
$317.94 /

-0.38 (-0.12%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AAPL Apple
$317.94 /

-0.38 (-0.12%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AAPL Apple
$317.94 /

-0.38 (-0.12%)

AMZN Amazon.com
$2,442.37 /

+42.04 (+1.75%)

AAPL Apple
$317.94 /

-0.38 (-0.12%)

Periodicals
KKR, Cinven, Providence seek to take over Masmovil, Bloomberg reports » 13:43
05/31/20
05/31
13:43
05/31/20
13:43
KKR

KKR

$27.81 /

-0.495 (-1.75%)

Three buyout funds are…

Three buyout funds are preparing a joint offer to take full control of Spanish carrier Masmovil Ibercom, Bloomberg's Rodrigo Orihuela, Manuel Baigorri and Jan-Henrik Foerster report, citing people familiar with the matter. KKR, Cinven and Providence Equity Partners plan to offer slightly more than $24 a share for the Spanish phone and internet company, according to the people. Reference Link

ShowHide Related Items >><<
KKR KKR
$27.81 /

-0.495 (-1.75%)

KKR KKR
$27.81 /

-0.495 (-1.75%)

05/07/20 Oppenheimer
KKR price target lowered to $34 from $41 at Oppenheimer
04/21/20
Envision bankruptcy report has limited read-throughs, says Benchmark
04/17/20 BMO Capital
BlackRock price target raised to $441 from $386 at BMO Capital
04/15/20 Wells Fargo
KKR price target lowered to $33 from $38 at Wells Fargo
KKR KKR
$27.81 /

-0.495 (-1.75%)

KKR KKR
$27.81 /

-0.495 (-1.75%)

KKR KKR
$27.81 /

-0.495 (-1.75%)

KKR KKR
$27.81 /

-0.495 (-1.75%)

Periodicals
SpaceX Crew Dragon docks with International Space Station, Reuters says » 13:28
05/31/20
05/31
13:28
05/31/20
13:28
TSLA

Tesla

$834.23 /

+28.38 (+3.52%)

Just under 19 hours after…

Just under 19 hours after launching from Florida, SpaceX's Crew Dragon capsule carrying NASA astronauts Bob Behnken and Doug Hurley docked with the International Space Station on Sunday, marking the first U.S. space capsule to do so with a crew since 2011, according to Reuters. The launch on Saturday by SpaceX, the private rocket company of Tesla's Elon Musk, represented another milestone for the reusable rockets it pioneered to make spaceflight less costly and more frequent, the publication notes. Reference Link

ShowHide Related Items >><<
TSLA Tesla
$834.23 /

+28.38 (+3.52%)

TSLA Tesla
$834.23 /

+28.38 (+3.52%)

05/29/20
Fly Intel: Top five analyst initiations
05/29/20 Daiwa
Tesla initiated with an Outperform at Daiwa
05/28/20 Morgan Stanley
Tesla shift to software revenue key to unlocking bull case, says Morgan Stanley
05/27/20 Roth Capital
Tesla's North American price cuts hint at weak demand, says Roth Capital
TSLA Tesla
$834.23 /

+28.38 (+3.52%)

TSLA Tesla
$834.23 /

+28.38 (+3.52%)

TSLA Tesla
$834.23 /

+28.38 (+3.52%)

TSLA Tesla
$834.23 /

+28.38 (+3.52%)

TSLA Tesla
$834.23 /

+28.38 (+3.52%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.